<DOC>
	<DOCNO>NCT00483652</DOCNO>
	<brief_summary>The purpose study show individual treat Fampridine-SR tablet significantly likely consistent improvement walk treat placebo tablet .</brief_summary>
	<brief_title>Study Fampridine-SR Tablets Multiple Sclerosis Patients</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) disorder body 's immune system affect central nervous system ( CNS ) . Normally , nerve fiber carry electrical impulse spinal cord , provide communication brain arm legs . In people MS , fatty sheath surround insulate nerve fiber ( call `` myelin '' ) deteriorate , cause nerve impulse slow stopped . As result , patient MS may experience period muscle weakness symptom numbness , loss vision , loss coordination , paralysis , spasticity , mental physical fatigue decrease ability think and/or remember . These period illness may come ( exacerbation ) go ( remission ) . Fampridine-SR experimental drug report possibly improve muscle strength walk ability people MS . This study evaluate effect possible risk take Fampridine-SR MS patient</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patient clinically define multiple sclerosis All patient must able complete two trial time 25 foot walk Female patient either pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>walk</keyword>
	<keyword>leg strength</keyword>
	<keyword>demyelination</keyword>
</DOC>